EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis

Kamyar Kalantar-Zadeh, Linda H Ficociello, Meijiao Zhou, Michael S Anger

BMC Nephrology · 2024

DOI: 10.1186/s12882-024-03633-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Nephrology, 2024. Verfasst von Kamyar Kalantar-Zadeh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension and Transplantation, Harbor-UCLA Medical Center and The Lundquist Institute, Torrance, CA, USA. Hauptthemen laut MEDLINE: Ferric Compounds, Phosphorus, Peritoneal Dialysis, Hyperphosphatemia. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fresenius Medical Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hyperphosphatemia is associated with increased morbidity and mortality in patients with end-stage kidney disease (ESKD). Whereas clinical and observational studies have demonstrated the effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus (sP) in ESKD, data on the real-world impact of switching to SO in patients on peritoneal dialysis (PD) are limited. In this retrospective database analysis, we examine the impact of SO on sP management over a 1-year period among PD patients prescribed SO as part of routine clinical care.

Methods

We analyzed de-identified data from adults on PD in Fresenius Kidney Care clinics who were prescribed SO monotherapy between May 2018 and December 2019 as part of routine clinical management. Changes from baseline in sP levels, phosphate binder (PB) pill burden, and laboratory parameters were evaluated during the four consecutive 91-day intervals of SO treatment.

Results

The mean age of the 402 patients who completed 1 year of SO was 55.2 years at baseline, and they had been on PD for an average of 19.9 months. SO was initiated with no baseline PB recorded in 36.1% of patients, whereas the remaining 257 patients were switched to SO from sevelamer (39.7%), calcium acetate (30.4%), lanthanum (1.2%), ferric citrate (14.0%), or more than one PB (14.8%). Mean sP at baseline was 6.26 mg/dL. After being prescribed SO, the percentage of patients achieving sP ≤ 5.5 mg/dL increased from 32.1% (baseline) to 46.5–54.0% during the 1-year follow-up, whereas the mean number of PB pills taken per day decreased from 7.7 at baseline (among patients on a baseline PB) to 4.6 to 5.4. Serum phosphorus and PB pill burden decreased regardless of changes in residual kidney function over the 12-month period. Similar results were observed for the full cohort (976 patients who either completed or discontinued SO during the 1-year follow-up).

Conclusions

Patients on PD who were prescribed SO as part of routine care for phosphorus management experienced significant reductions in SP and PB pills per day and improvements in sP target achievement, suggesting the effectiveness of SO on SP management with a concurrent reduction in pill burden.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ferric CompoundsPhosphorusPeritoneal DialysisHyperphosphatemiaKidney Failure, ChronicHumansMiddle AgedMaleRetrospective StudiesFemaleFollow-Up StudiesSucroseDrug CombinationsAgedAdult

Stichwörter der Autor:innen

HyperphosphatemiaPeritoneal dialysisPhosphate binderPhosphorusPill burdenSucroferric oxyhydroxide

Substanzen

sucroferric oxyhydroxideFerric CompoundsPhosphorusSucroseDrug Combinations

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension and Transplantation, Harbor-UCLA Medical Center and The Lundquist Institute, Torrance, CA, USA.
  • Fresenius Medical Care, Global Medical Office, Waltham, MA, USA.
  • Fresenius Medical Care, Global Medical Office, Waltham, MA, USA. michael.anger@freseniusmedicalcare.com.

Förderung

  • Fresenius Medical Care

Zitieren

APA

Kalantar-Zadeh, K., Ficociello, L. H., Zhou, M., & Anger, M. S. (2024). Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis. BMC Nephrology. https://doi.org/10.1186/s12882-024-03633-8

Vancouver

Kalantar-Zadeh K, Ficociello LH, Zhou M, Anger MS. Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis. BMC Nephrology. 2024. doi:10.1186/s12882-024-03633-8

BibTeX
@article{KalantarZadeh2024,
  author = {Kalantar-Zadeh, Kamyar and Ficociello, Linda H and Zhou, Meijiao and Anger, Michael S},
  title = {Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis},
  journal = {BMC Nephrology},
  year = {2024},
  doi = {10.1186/s12882-024-03633-8}
}
Kostenlos starten →